ISDA

Deposition Date 2011-09-29

Release Date 2011-12-21

Last Version Date 2023-12-20

Entry Detail

PDB ID:

4A2Z

Keywords:

TRANSFERASE

Title:

CRYSTAL STRUCTURE OF LEISHMANIA MAJOR N-MYRISTOYLTRANSFERASE (NMT) WITH BOUND MYRISTOYL-COA AND A PYRAZOLE SULPHONAMIDE LIGAND

Biological Source:

Source Organism:

LEISHMANIA MAJOR (Taxon ID: 5664)

Host Organism:

ESCHERICHIA COLI

Method Details:

Experimental Method:

X-RAY DIFFRACTION

Resolution:

2.31 Å

R-Value Free:

0.22

R-Value Work:

0.16

R-Value Observed:

0.16

Space Group:

P 1 21 1

Download Validation Report

Macromolecular Entities

Protein Blast

Polymer Type:polypeptide(L)
Molecule:GLYCYLPEPTIDE N-TETRADECANOYLTRANSFERASE
Gene (Uniprot):NMT
Chain IDs:A
Chain Length:438
Number of Molecules:1
Biological Source:LEISHMANIA MAJOR

UniProt ID:Q4Q5S8 Pfam ID:PF01233, PF02799 EC:2.3.1.97

Ligand Molecules

GOL

MYA

VIQ

Primary Citation

Discovery of a novel class of orally active trypanocidal N-myristoyltransferase inhibitors.

Brand, S, Cleghorn, L.A, McElroy, S.P, Robinson, D.A, Smith, V.C, Hallyburton, I, Harrison, J.R, Norcross, N.R, Spinks, D, Bayliss, T, Norval, S, Stojanovski, L, Torrie, L.S, Frearson, J.A, Brenk, R, Fairlamb, A.H, Ferguson, M.A, Read, K.D, Wyatt, P.G, Gilbert, I.H, Frearson, J.A, Brand, S, Mcelroy, S.P, Cleghorn, L.A.T, Smid, O, Stojanovski, L, Price, H.P, Guther, M.L.S, Torrie, L.S, Robinson, D.A, Hallyburton, I, Mpamhanga, C.P, Brannigan, J.A, Wilkinson, A.J, Hodgkinson, M, Hui, R, Qiu, W, Raimi, O.G, Van Aalten, D.M.F, Brenk, R, Gilbert, I.H, Read, K.D, Fairlamb, A.H, Ferguson, M.A.J, Smith, D.F, Wyatt, P.G.Show

J. Med. Chem. 55 140 152 (2012)

PMID: 22148754 DOI: 10.1021/jm201091t

Abstact

N-Myristoyltransferase (NMT) represents a promising drug target for human African trypanosomiasis (HAT), which is caused by the parasitic protozoa Trypanosoma brucei. We report the optimization of a high throughput screening hit (1) to give a lead molecule DDD85646 (63), which has potent activity against the enzyme (IC(50) = 2 nM) and T. brucei (EC(50) = 2 nM) in culture. The compound has good oral pharmacokinetics and cures rodent models of peripheral HAT infection. This compound provides an excellent tool for validation of T. brucei NMT as a drug target for HAT as well as a valuable lead for further optimization.

Legend

Protein

Chemical

Disease

Primary Citation of related structures